A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of HLX26 Monoclonal Antibody Injection in Patients With Solid Tumor or Lymphoma

Summary

This study is a first-in-class open-label phase I human clinical study to evaluate the safety and tolerability of HLX26 with escalated doses in the treatment of patients with advanced/metastatic solid tumors or lymphomas.

Timeline

Start

2021-10-11

Primary completion

2023-08-18

Completion

2023-08-18

Publications

• Liu R, Jing H, Chen Y, Gao S, Zhang J, Cao X, Li K, Liu Y, Meng M, Chen C, Sun C, Yu H, Wang Q, Li J, Wu Y, Zhang J. Phase I Studies of HLX26, A Novel Anti-LAG-3 Antibody, Monotherapy or Combination Therapy in Patients with Advanced Solid Tumors. BioDrugs. 2026 Mar;40(2):335-348. doi: 10.1007/s40259-025-00751-z. Epub 2026 Jan 15.

Drugs

Indications